Q1 group results (IFRS)
May 12 (Reuters)-
Sosei Group Corp
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2023 Mar 31, 2022 Dec 31, 2023
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 943 mln 1.12
(-15.7 pct) (-7.3 pct)
Operating loss 1.96 loss 2.21
Pretax loss 1.86 loss 2.50
Net loss 1.40 loss 2.07
EPS Basic loss 17.11 yen loss 25.39 yen
EPS Diluted loss 17.11 yen loss 25.39 yen
Ann Div NIL NIL
-Q2 Div NIL NIL
-Q4 Div NIL NIL
NOTE - Sosei Group Corp.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up